AbbVie said new information about Imbruvica (ibrutinib) shows that it is stronger than chlorambucil in fighting chronic lymphocytic leukemia in certain patients.
AbbVie said in a release that according to the findings it presented at the 2017 annual Meeting of the American Society of Clinical Oncology, Imbruvica fought cancer cells and lowered the number of cancer cells that could help chronic lymphocytic leukemia grow in the bodies of patients. The findings also showed that Imbruvica left healthy white blood cells alone, the release said.
Imbruvica cut down on 90 percent of cancer cells and immunosuppressive tumor microenvironment chronic lymphocytic leukemia cells, 61 percent of myeloid-derived suppressor cells and 27 to 52 percent of T cells, the release said. AbbVie also presented information that showed that Imbruvica drove up classical-monocyte numbers 187 percent.
AbbVie said it presented information showing that chlorambucil targeted many groups of immune cells whether they were cancer cells or not.
These findings were based patients fighting chronic lymphocytic leukemia with Imbruvica for a year.